Ph样急性淋巴细胞白血病的研究进展  

Research progress of Ph-like acute lymphoblastic leukemia

作　　者：杨丽喆 张燕[1] 王季石[1] YANG Li-zhe;ZHANG Yan;WANG Ji-shi(Guizhou Medical University,Guiyang 550004,China)

机构地区：[1]贵州医科大学,贵州贵阳550004

出　　处：《临床医学研究与实践》2020年第10期197-198,共2页Clinical Research and Practice

摘　　要：费城染色体样(Ph样)急性淋巴细胞白血病(ALL)是近年发现的B系ALL的高危亚型,其基因改变通常可引起酪氨酸激酶信号或细胞因子受体的激活并级联放大,从而导致下游ABL和JAK/STAT通路被激活。本文就目前Ph样ALL的研究进展做一概述。Philadelphia-like(Ph-like)acute lymphoblastic leukemia(ALL)is a recently discovered high-risk subtype of b-type ALL.Its genetic changes usually result in activation and cascade amplification of tyrosine kinase signaling or cytokine receptors,resulting in activation of downstream ABL and JAK/STAT pathways.This paper summarizes the research progress of Ph-like ALL.

关 键 词：费城染色体样急性淋巴细胞白血病 基因 激酶抑制剂 

分 类 号：R733.71[医药卫生—肿瘤]